Heron Therapeutics, Inc. (HRTX)
USD 1.9
(4.4%)
USD 1.9
(4.4%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 222.5 Million USD | -11.33% |
| 2022 | 250.95 Million USD | -17.91% |
| 2021 | 305.7 Million USD | -13.53% |
| 2020 | 353.55 Million USD | -31.05% |
| 2019 | 512.78 Million USD | 10.95% |
| 2018 | 462.17 Million USD | 97.25% |
| 2017 | 234.3 Million USD | 247.21% |
| 2016 | 67.48 Million USD | -51.05% |
| 2015 | 137.84 Million USD | 79.76% |
| 2014 | 76.68 Million USD | 0.98% |
| 2013 | 75.93 Million USD | 35.67% |
| 2012 | 55.97 Million USD | 187.85% |
| 2011 | 19.44 Million USD | 567.98% |
| 2010 | 2.91 Million USD | -67.48% |
| 2009 | 8.95 Million USD | -24.14% |
| 2008 | 11.8 Million USD | -68.06% |
| 2007 | 36.95 Million USD | 114.19% |
| 2006 | 17.25 Million USD | 92.34% |
| 2005 | 8.96 Million USD | -47.28% |
| 2004 | 17.01 Million USD | 29.33% |
| 2003 | 13.15 Million USD | -26.09% |
| 2002 | 17.79 Million USD | -24.28% |
| 2001 | 23.5 Million USD | -12.92% |
| 2000 | 26.99 Million USD | 14.88% |
| 1999 | 23.5 Million USD | 1.73% |
| 1998 | 23.1 Million USD | -4.55% |
| 1997 | 24.2 Million USD | 31.52% |
| 1996 | 18.4 Million USD | -20.35% |
| 1995 | 23.1 Million USD | -1.7% |
| 1994 | 23.5 Million USD | -3.69% |
| 1993 | 24.4 Million USD | -13.78% |
| 1992 | 28.3 Million USD | 194.79% |
| 1991 | 9.6 Million USD | -17.24% |
| 1990 | 11.6 Million USD | -12.12% |
| 1989 | 13.2 Million USD | -21.43% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 217.88 Million USD | -2.08% |
| 2024 Q2 | 218.13 Million USD | 0.11% |
| 2023 Q3 | 229.19 Million USD | 13.9% |
| 2023 Q1 | 220.87 Million USD | -11.98% |
| 2023 Q2 | 201.22 Million USD | -8.9% |
| 2023 FY | 222.5 Million USD | -11.33% |
| 2023 Q4 | 222.5 Million USD | -2.92% |
| 2022 Q3 | 271.95 Million USD | 11.47% |
| 2022 Q4 | 250.95 Million USD | -7.72% |
| 2022 Q2 | 243.96 Million USD | -10.87% |
| 2022 FY | 250.95 Million USD | -17.91% |
| 2022 Q1 | 273.72 Million USD | -10.46% |
| 2021 FY | 305.7 Million USD | -13.53% |
| 2021 Q3 | 352.38 Million USD | -12.83% |
| 2021 Q2 | 404.25 Million USD | 30.01% |
| 2021 Q1 | 310.93 Million USD | -12.06% |
| 2021 Q4 | 305.7 Million USD | -13.25% |
| 2020 Q1 | 478.94 Million USD | -6.6% |
| 2020 Q3 | 390.02 Million USD | -9.87% |
| 2020 Q4 | 353.55 Million USD | -9.35% |
| 2020 FY | 353.55 Million USD | -31.05% |
| 2020 Q2 | 432.72 Million USD | -9.65% |
| 2019 Q4 | 512.78 Million USD | 30.49% |
| 2019 FY | 512.78 Million USD | 10.95% |
| 2019 Q3 | 392.96 Million USD | -4.54% |
| 2019 Q2 | 411.66 Million USD | -5.54% |
| 2019 Q1 | 435.79 Million USD | -5.71% |
| 2018 Q2 | 510.55 Million USD | 178.41% |
| 2018 FY | 462.17 Million USD | 97.25% |
| 2018 Q4 | 462.17 Million USD | -1.85% |
| 2018 Q3 | 470.89 Million USD | -7.77% |
| 2018 Q1 | 183.38 Million USD | -21.73% |
| 2017 Q4 | 234.3 Million USD | 98.24% |
| 2017 FY | 234.3 Million USD | 247.21% |
| 2017 Q1 | 189.55 Million USD | 180.9% |
| 2017 Q2 | 142.37 Million USD | -24.89% |
| 2017 Q3 | 118.19 Million USD | -16.98% |
| 2016 Q3 | 98.8 Million USD | 15.25% |
| 2016 Q2 | 85.73 Million USD | -23.35% |
| 2016 FY | 67.48 Million USD | -51.05% |
| 2016 Q1 | 111.84 Million USD | -18.86% |
| 2016 Q4 | 67.48 Million USD | -31.7% |
| 2015 Q2 | 176.45 Million USD | 195.93% |
| 2015 Q1 | 59.62 Million USD | -22.24% |
| 2015 Q3 | 158.15 Million USD | -10.37% |
| 2015 Q4 | 137.84 Million USD | -12.84% |
| 2015 FY | 137.84 Million USD | 79.76% |
| 2014 FY | 76.68 Million USD | 0.98% |
| 2014 Q1 | 62.79 Million USD | -17.31% |
| 2014 Q4 | 76.68 Million USD | -16.9% |
| 2014 Q3 | 92.28 Million USD | -15.06% |
| 2014 Q2 | 108.63 Million USD | 73.01% |
| 2013 Q2 | 38.09 Million USD | -22.23% |
| 2013 Q3 | 26.37 Million USD | -30.77% |
| 2013 Q4 | 75.93 Million USD | 187.97% |
| 2013 FY | 75.93 Million USD | 35.67% |
| 2013 Q1 | 48.97 Million USD | -12.49% |
| 2012 FY | 55.97 Million USD | 187.85% |
| 2012 Q1 | 14.99 Million USD | -22.89% |
| 2012 Q3 | 61.76 Million USD | 333.99% |
| 2012 Q2 | 14.23 Million USD | -5.09% |
| 2012 Q4 | 55.97 Million USD | -9.37% |
| 2011 Q4 | 19.44 Million USD | -10.79% |
| 2011 FY | 19.44 Million USD | 567.98% |
| 2011 Q3 | 21.79 Million USD | -1.47% |
| 2011 Q2 | 22.12 Million USD | 1086.11% |
| 2011 Q1 | 1.86 Million USD | -35.93% |
| 2010 Q2 | 6.85 Million USD | -22.18% |
| 2010 FY | 2.91 Million USD | -67.48% |
| 2010 Q1 | 8.8 Million USD | -1.63% |
| 2010 Q3 | 4.08 Million USD | -40.32% |
| 2010 Q4 | 2.91 Million USD | -28.81% |
| 2009 Q3 | 3.03 Million USD | -36.62% |
| 2009 Q4 | 8.95 Million USD | 194.73% |
| 2009 FY | 8.95 Million USD | -24.14% |
| 2009 Q2 | 4.79 Million USD | -44.52% |
| 2009 Q1 | 8.63 Million USD | -26.81% |
| 2008 Q3 | 18.05 Million USD | -22.92% |
| 2008 Q4 | 11.8 Million USD | -34.65% |
| 2008 Q2 | 23.42 Million USD | -21.05% |
| 2008 Q1 | 29.67 Million USD | -19.69% |
| 2008 FY | 11.8 Million USD | -68.06% |
| 2007 FY | 36.95 Million USD | 114.19% |
| 2007 Q4 | 36.95 Million USD | -11.25% |
| 2007 Q2 | 46.71 Million USD | 326.13% |
| 2007 Q1 | 10.96 Million USD | -36.46% |
| 2007 Q3 | 41.63 Million USD | -10.87% |
| 2006 Q2 | 23.49 Million USD | -15.62% |
| 2006 FY | 17.25 Million USD | 92.34% |
| 2006 Q4 | 17.25 Million USD | -13.52% |
| 2006 Q3 | 19.94 Million USD | -15.1% |
| 2006 Q1 | 27.84 Million USD | 210.47% |
| 2005 Q1 | 14.89 Million USD | -12.43% |
| 2005 FY | 8.96 Million USD | -47.28% |
| 2005 Q4 | 8.96 Million USD | -20.15% |
| 2005 Q3 | 11.23 Million USD | -12.73% |
| 2005 Q2 | 12.87 Million USD | -13.61% |
| 2004 FY | 17.01 Million USD | 29.33% |
| 2004 Q1 | 11.26 Million USD | -14.35% |
| 2004 Q2 | 20.05 Million USD | 77.99% |
| 2004 Q3 | 18.57 Million USD | -7.36% |
| 2004 Q4 | 17.01 Million USD | -8.42% |
| 2003 Q3 | 14.67 Million USD | -7.73% |
| 2003 FY | 13.15 Million USD | -26.09% |
| 2003 Q1 | 18.07 Million USD | 1.56% |
| 2003 Q2 | 15.9 Million USD | -11.99% |
| 2003 Q4 | 13.15 Million USD | -10.38% |
| 2002 Q4 | 17.79 Million USD | -5.89% |
| 2002 FY | 17.79 Million USD | -24.28% |
| 2002 Q1 | 21.69 Million USD | -7.72% |
| 2002 Q3 | 18.91 Million USD | -7.58% |
| 2002 Q2 | 20.46 Million USD | -5.66% |
| 2001 Q1 | 25.06 Million USD | -7.14% |
| 2001 Q4 | 23.5 Million USD | -5.12% |
| 2001 Q2 | 23.92 Million USD | -4.57% |
| 2001 FY | 23.5 Million USD | -12.92% |
| 2001 Q3 | 24.77 Million USD | 3.56% |
| 2000 Q3 | 29 Million USD | 55.56% |
| 2000 Q4 | 26.99 Million USD | -6.93% |
| 2000 Q2 | 18.64 Million USD | -17.08% |
| 2000 Q1 | 22.48 Million USD | -4.31% |
| 2000 FY | 26.99 Million USD | 14.88% |
| 1999 Q1 | 24.9 Million USD | 7.79% |
| 1999 Q2 | 23.7 Million USD | -4.82% |
| 1999 Q3 | 23.7 Million USD | 0.0% |
| 1999 Q4 | 23.5 Million USD | -0.84% |
| 1999 FY | 23.5 Million USD | 1.73% |
| 1998 Q4 | 23.1 Million USD | -2.53% |
| 1998 Q1 | 24.6 Million USD | 1.65% |
| 1998 FY | 23.1 Million USD | -4.55% |
| 1998 Q2 | 24.4 Million USD | -0.81% |
| 1998 Q3 | 23.7 Million USD | -2.87% |
| 1997 Q3 | 22.4 Million USD | 6.67% |
| 1997 Q1 | 19.6 Million USD | 6.52% |
| 1997 FY | 24.2 Million USD | 31.52% |
| 1997 Q2 | 21 Million USD | 7.14% |
| 1997 Q4 | 24.2 Million USD | 8.04% |
| 1996 FY | 18.4 Million USD | -20.35% |
| 1996 Q4 | 18.4 Million USD | -21.7% |
| 1996 Q1 | 24.6 Million USD | 6.49% |
| 1996 Q3 | 23.5 Million USD | -7.48% |
| 1996 Q2 | 25.4 Million USD | 3.25% |
| 1995 Q3 | 26.8 Million USD | 3.88% |
| 1995 Q4 | 23.1 Million USD | -13.81% |
| 1995 FY | 23.1 Million USD | -1.7% |
| 1995 Q1 | 27.9 Million USD | 18.72% |
| 1995 Q2 | 25.8 Million USD | -7.53% |
| 1994 Q2 | 30.1 Million USD | 7.89% |
| 1994 Q1 | 27.9 Million USD | 14.34% |
| 1994 Q4 | 23.5 Million USD | -8.91% |
| 1994 FY | 23.5 Million USD | -3.69% |
| 1994 Q3 | 25.8 Million USD | -14.29% |
| 1993 Q1 | 26.4 Million USD | -6.71% |
| 1993 FY | 24.4 Million USD | -13.78% |
| 1993 Q2 | 31.7 Million USD | 20.08% |
| 1993 Q3 | 25.8 Million USD | -18.61% |
| 1993 Q4 | 24.4 Million USD | -5.43% |
| 1992 Q4 | 28.3 Million USD | -5.35% |
| 1992 Q2 | 24.5 Million USD | 19.51% |
| 1992 Q1 | 20.5 Million USD | 113.54% |
| 1992 FY | 28.3 Million USD | 194.79% |
| 1992 Q3 | 29.9 Million USD | 22.04% |
| 1991 Q2 | 10 Million USD | -1.96% |
| 1991 FY | 9.6 Million USD | -17.24% |
| 1991 Q3 | 9.1 Million USD | -9.0% |
| 1991 Q4 | 9.6 Million USD | 5.49% |
| 1991 Q1 | 10.2 Million USD | -12.07% |
| 1990 Q2 | 11.9 Million USD | -3.25% |
| 1990 Q4 | 11.6 Million USD | 8.41% |
| 1990 Q3 | 10.7 Million USD | -10.08% |
| 1990 FY | 11.6 Million USD | -12.12% |
| 1990 Q1 | 12.3 Million USD | -6.82% |
| 1989 FY | 13.2 Million USD | -21.43% |
| 1989 Q4 | 13.2 Million USD | -8.33% |
| 1989 Q2 | 15.4 Million USD | 0.0% |
| 1989 Q3 | 14.4 Million USD | -6.49% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Caribou Biosciences, Inc. | 440.96 Million USD | 49.541% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | -1433.821% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -2592.799% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | -292.482% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | 46.234% |
| C4 Therapeutics, Inc. | 376.45 Million USD | 40.894% |
| Agenus Inc. | 313.91 Million USD | 29.119% |
| Fortress Biotech, Inc. | 167.52 Million USD | -32.819% |
| GlycoMimetics, Inc. | 45.31 Million USD | -391.005% |
| Novavax, Inc. | 1.85 Billion USD | 88.007% |
| Keros Therapeutics, Inc. | 370.02 Million USD | 39.867% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | -601.027% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | 50.886% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | 52.577% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | 7.942% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 94.19% |
| AlloVir, Inc. | 190.79 Million USD | -16.62% |
| Aptorum Group Limited | 20.64 Million USD | -978.028% |
| Ardelyx, Inc. | 297.57 Million USD | 25.228% |
| Bicycle Therapeutics plc | 595.34 Million USD | 62.626% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | -201.9% |
| Chimerix, Inc. | 212.77 Million USD | -4.574% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -687.008% |
| CRISPR Therapeutics AG | 2.22 Billion USD | 90.02% |
| Clearside Biomedical, Inc. | 34.01 Million USD | -554.083% |
| Precision BioSciences, Inc. | 159.78 Million USD | -39.257% |
| Dyadic International, Inc. | 8.21 Million USD | -2607.137% |
| Elevation Oncology, Inc. | 89.09 Million USD | -149.751% |
| Fortress Biotech, Inc. | 167.52 Million USD | -32.819% |
| GT Biopharma, Inc. | 14.1 Million USD | -1477.05% |
| Alkermes plc | 2.13 Billion USD | 89.584% |
| Immix Biopharma, Inc. | 19.92 Million USD | -1016.709% |
| Innoviva, Inc. | 1.24 Billion USD | 82.107% |
| IO Biotech, Inc. | 150.71 Million USD | -47.631% |
| Jaguar Health, Inc. | 50.76 Million USD | -338.323% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | 73.291% |
| ContextLogic Inc. | 423 Million USD | 47.398% |
| AbCellera Biologics Inc. | 1.48 Billion USD | 85.048% |
| Lantern Pharma Inc. | 43.64 Million USD | -409.778% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -3487.649% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | 70.935% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | 65.263% |
| MEI Pharma, Inc. | 41.37 Million USD | -437.779% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | -3.729% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -1075.808% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | -30.191% |
| NextCure, Inc. | 129.41 Million USD | -71.928% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | -37.914% |
| ChromaDex Corporation | 54.96 Million USD | -304.821% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | 65.732% |
| Incyte Corporation | 6.78 Billion USD | 96.719% |
| Opthea Limited | 188.79 Million USD | -17.858% |
| MiMedx Group, Inc. | 239.04 Million USD | 6.92% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | -588.852% |
| Aadi Bioscience, Inc. | 132.42 Million USD | -68.027% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -19553.247% |
| Vaxcyte, Inc. | 1.4 Billion USD | 84.196% |
| PDS Biotechnology Corporation | 59.39 Million USD | -274.652% |
| Pharming Group N.V. | 462.85 Million USD | 51.927% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | -475.248% |
| Onconetix, Inc. | 88.82 Million USD | -150.509% |
| Acelyrin, Inc. | 742.69 Million USD | 70.041% |
| PureTech Health plc | 693.97 Million USD | 67.937% |
| Pyxis Oncology, Inc. | 173.72 Million USD | -28.079% |
| Avidity Biosciences, Inc. | 628.55 Million USD | 64.6% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -4204.04% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -1075.808% |
| ESSA Pharma Inc. | 149.12 Million USD | -49.211% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | -89.811% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | -312.445% |
| Seer, Inc. | 436.26 Million USD | 48.998% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -34.591% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -3375.027% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | -391.324% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -3278.201% |
| Summit Therapeutics Inc. | 202.94 Million USD | -9.636% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | -199.172% |
| Senti Biosciences, Inc. | 119.48 Million USD | -86.222% |
| ImmuCell Corporation | 43.8 Million USD | -407.911% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | -32.307% |
| Janux Therapeutics, Inc. | 380.4 Million USD | 41.508% |
| Precigen, Inc. | 151.04 Million USD | -47.313% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | -338.894% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | -505.805% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | 2.556% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | 34.71% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -4561.014% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | 52.943% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | -172.689% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | -79.944% |
| VYNE Therapeutics Inc. | 97.68 Million USD | -127.779% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -586.62% |
| Wave Life Sciences Ltd. | 274.94 Million USD | 19.074% |
| Fate Therapeutics, Inc. | 506.21 Million USD | 56.045% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -2101.94% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | 27.733% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | 52.85% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | -133.695% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -35129.612% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | 60.712% |
| Aptose Biosciences Inc. | 12.92 Million USD | -1621.844% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | -906.164% |
| Soligenix, Inc. | 9.79 Million USD | -2171.089% |
| Century Therapeutics, Inc. | 360.69 Million USD | 38.311% |
| Kura Oncology, Inc. | 448.93 Million USD | 50.437% |
| TScan Therapeutics, Inc. | 272.14 Million USD | 18.241% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | -1186.534% |
| Ocean Biomedical, Inc. | 110.91 Million USD | -100.616% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | -8.46% |
| Autolus Therapeutics plc | 375.38 Million USD | 40.725% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | 11.576% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | 37.355% |
| Eterna Therapeutics Inc. | 49.13 Million USD | -352.874% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | 66.345% |
| GRI Bio, Inc. | 2.95 Million USD | -7427.267% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -1998.079% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | -30.491% |
| IGM Biosciences, Inc. | 423.41 Million USD | 47.449% |
| INmune Bio, Inc. | 57 Million USD | -290.355% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -165.073% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -751.963% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -3132.598% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | -195.783% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | -51.099% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -34.441% |
| Coherus BioSciences, Inc. | 629.6 Million USD | 64.659% |
| Verastem, Inc. | 149.71 Million USD | -48.617% |
| Abeona Therapeutics Inc. | 64 Million USD | -247.655% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | 56.555% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | -44.057% |
| Histogen Inc. | 19.07 Million USD | -1066.602% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | -882.359% |
| Surrozen, Inc. | 46.08 Million USD | -382.869% |
| Organovo Holdings, Inc. | 6.34 Million USD | -3404.583% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -5064.206% |
| Ovid Therapeutics Inc. | 144.02 Million USD | -54.489% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -1785.325% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | -195.618% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -2511.803% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | 38.698% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | -1129.696% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | 48.182% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | -1664.28% |
| Apollomics, Inc. | 55.38 Million USD | -301.73% |
| Amarin Corporation plc | 831.68 Million USD | 73.246% |
| Mesoblast Limited | 669.15 Million USD | 66.748% |
| Turnstone Biologics Corp. | 112.81 Million USD | -97.231% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | 61.354% |
| Synaptogenix, Inc. | 31.11 Million USD | -615.139% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | -1726.215% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | 59.401% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -3689.103% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -2929.288% |
| Exelixis, Inc. | 2.94 Billion USD | 92.438% |
| Better Therapeutics, Inc. | 22.94 Million USD | -869.821% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | 38.962% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | 71.789% |
| NLS Pharmaceutics AG | 1.84 Million USD | -11949.229% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -2688.773% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -1414.161% |
| Gritstone bio, Inc. | 177.76 Million USD | -25.166% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -133.284% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | -1145.676% |
| Avid Bioservices, Inc. | 336.55 Million USD | 33.888% |
| Insmed Incorporated | 1.32 Billion USD | 83.268% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -2210.948% |
| MediWound Ltd. | 66.45 Million USD | -234.802% |
| OmniAb, Inc. | 401.98 Million USD | 44.648% |
| Alector, Inc. | 621.82 Million USD | 64.217% |
| Seres Therapeutics, Inc. | 358.6 Million USD | 37.951% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -4037.337% |
| Zai Lab Limited | 1.03 Billion USD | 78.529% |
| Revance Therapeutics, Inc. | 478.45 Million USD | 53.495% |
| Aura Biosciences, Inc. | 255.07 Million USD | 12.768% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | 70.334% |
| Immunic, Inc. | 54.29 Million USD | -309.779% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | 16.422% |
| Veracyte, Inc. | 1.13 Billion USD | 80.445% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | -1782.011% |
| FibroGen, Inc. | 423.52 Million USD | 47.464% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -6233.789% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -4597.584% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -3998.11% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 98.047% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -2427.041% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | 57.0% |
| TG Therapeutics, Inc. | 329.58 Million USD | 32.489% |
| Galecto, Inc. | 38.22 Million USD | -482.065% |
| Calithera Biosciences, Inc. | 28.67 Million USD | -675.931% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 94.893% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | 5.479% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | -795.685% |
| XBiotech Inc. | 227.24 Million USD | 2.085% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -133.284% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | -56.035% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | 22.178% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | -74.011% |
| Theravance Biopharma, Inc. | 381.99 Million USD | 41.752% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | 85.077% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | 39.013% |
| Vaxxinity, Inc. | 44.35 Million USD | -401.671% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | 56.959% |
| Gain Therapeutics, Inc. | 18.6 Million USD | -1095.669% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | 27.059% |
| NexImmune, Inc. | 8.59 Million USD | -2489.101% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -1976.547% |
| Marker Therapeutics, Inc. | 17.12 Million USD | -1199.124% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 99.327% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | -904.49% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -56623.389% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | -28.372% |
| Ainos, Inc. | 31.84 Million USD | -598.786% |
| Pluri Inc. | 39.52 Million USD | -462.922% |
| Prothena Corporation plc | 696.38 Million USD | 68.048% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | 21.269% |
| Celularity Inc. | 143.88 Million USD | -54.637% |
| Rallybio Corporation | 115.62 Million USD | -92.446% |
| Cue Biopharma, Inc. | 61.53 Million USD | -261.622% |
| MeiraGTx Holdings plc | 458.16 Million USD | 51.436% |
| Omeros Corporation | 378.26 Million USD | 41.178% |
| Humacyte, Inc. | 128.22 Million USD | -73.53% |
| Immunocore Holdings plc | 597 Million USD | 62.729% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | -611.814% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | -224.684% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 78.794% |
| CalciMedica, Inc. | 12.18 Million USD | -1726.065% |
| Cabaletta Bio, Inc. | 253.65 Million USD | 12.278% |
| Scholar Rock Holding Corporation | 311.03 Million USD | 28.463% |
| Sana Biotechnology, Inc. | 565.29 Million USD | 60.639% |
| Pulmatrix, Inc. | 33.95 Million USD | -555.239% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | -719.664% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | -57.965% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 82.897% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | -70.91% |
| Cytokinetics, Incorporated | 824.31 Million USD | 73.007% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -953.383% |
| Nutriband Inc. | 7.51 Million USD | -2859.977% |
| Protara Therapeutics, Inc. | 78.95 Million USD | -181.817% |
| Vor Biopharma Inc. | 209.82 Million USD | -6.042% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 96.919% |
| Evogene Ltd. | 51.1 Million USD | -335.424% |
| ProKidney Corp. | 420.55 Million USD | 47.092% |
| Applied Therapeutics, Inc. | 54.83 Million USD | -305.788% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -2237.18% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | 59.276% |
| CorMedix Inc. | 82.05 Million USD | -171.151% |
| BioLineRx Ltd. | 63.92 Million USD | -248.074% |
| Tango Therapeutics, Inc. | 402.56 Million USD | 44.728% |
| Galectin Therapeutics Inc. | 28.2 Million USD | -689.028% |
| Atai Life Sciences N.V. | 293.47 Million USD | 24.183% |
| Renovaro Biosciences Inc. | 163.12 Million USD | -36.398% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | -74.627% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | 60.41% |
| Sagimet Biosciences Inc. | 96.71 Million USD | -130.054% |
| MediciNova, Inc. | 66.26 Million USD | -235.757% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | -152.997% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -4886.28% |
| GeoVax Labs, Inc. | 9.28 Million USD | -2296.863% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 62.174% |
| Biomea Fusion, Inc. | 199.92 Million USD | -11.294% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | 88.309% |
| Mereo BioPharma Group plc | 66.49 Million USD | -234.601% |
| Cullinan Oncology, Inc. | 485.09 Million USD | 54.132% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | 63.695% |
| Absci Corporation | 234.48 Million USD | 5.107% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -2941.777% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | 34.536% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | -34.785% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | 57.724% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | 19.873% |
| Allakos Inc. | 243.61 Million USD | 8.663% |
| Imunon, Inc. | 21.91 Million USD | -915.172% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | 13.655% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 64.2% |
| BioAtla, Inc. | 119.65 Million USD | -85.952% |
| NLS Pharmaceutics AG | 1.84 Million USD | -11949.229% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -6810.124% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | 65.387% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | -131.934% |
| XOMA Corporation | 234.3 Million USD | 5.034% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | -0.575% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -76.811% |
| aTyr Pharma, Inc. | 122.06 Million USD | -82.282% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | -44.575% |
| Akero Therapeutics, Inc. | 580.27 Million USD | 61.655% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | 54.63% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | -101.419% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | -1367.954% |
| Akari Therapeutics, Plc | 4.35 Million USD | -5009.208% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -1205.991% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 87.163% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -7114.884% |
| UroGen Pharma Ltd. | 178.31 Million USD | -24.785% |
| Sutro Biopharma, Inc. | 470.73 Million USD | 52.732% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -39939.589% |
| Orgenesis Inc. | 14.55 Million USD | -1429.041% |
| Entera Bio Ltd. | 11.76 Million USD | -1791.254% |
| GH Research PLC | 226.3 Million USD | 1.677% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | -306.82% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | -107.106% |
| Xencor, Inc. | 952.69 Million USD | 76.644% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -2758.589% |
| Replimune Group, Inc. | 487.72 Million USD | 54.379% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -2656.827% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | 65.686% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -7114.884% |
| Portage Biotech Inc. | 7.77 Million USD | -2760.342% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -4886.28% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | 19.657% |
| OncoCyte Corporation | 74.89 Million USD | -197.102% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -10843.377% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -3745.165% |
| Purple Biotech Ltd. | 44.3 Million USD | -402.248% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | -552.013% |
| scPharmaceuticals Inc. | 94.47 Million USD | -135.508% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | -1133.065% |
| HilleVax, Inc. | 344.43 Million USD | 35.4% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -6905.856% |
| Tharimmune, Inc. | 10.94 Million USD | -1932.688% |
| Genprex, Inc. | 10.67 Million USD | -1985.226% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | 55.158% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | -131.17% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -9071.723% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -5241.715% |
| OKYO Pharma Limited | 1.54 Million USD | -14336.592% |
| Savara Inc. | 177.56 Million USD | -25.31% |
| Curis, Inc. | 77.28 Million USD | -187.914% |
| Daré Bioscience, Inc. | 21.28 Million USD | -945.502% |
| Carmell Therapeutics Corporation | 63.94 Million USD | -247.944% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -2651.744% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | -1048.655% |
| BeiGene, Ltd. | 5.8 Billion USD | 96.167% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -1728.466% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | 89.347% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | 37.839% |
| Erasca, Inc. | 395.29 Million USD | 43.712% |
| bluebird bio, Inc. | 619.16 Million USD | 64.063% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -5046.588% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 96.748% |
| DBV Technologies S.A. | 182.98 Million USD | -21.597% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -5046.588% |
| Moderna, Inc. | 18.42 Billion USD | 98.792% |
| Vincerx Pharma, Inc. | 18.21 Million USD | -1121.42% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -1820.473% |
| Molecular Templates, Inc. | 35.38 Million USD | -528.85% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | -60.927% |
| Travere Therapeutics, Inc. | 788.91 Million USD | 71.796% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | 26.748% |
| Spruce Biosciences, Inc. | 103.94 Million USD | -114.059% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | 52.214% |
| Cogent Biosciences, Inc. | 313.43 Million USD | 29.011% |
| MacroGenics, Inc. | 306.82 Million USD | 27.48% |
| RenovoRx, Inc. | 1.46 Million USD | -15077.763% |
| Adicet Bio, Inc. | 207.29 Million USD | -7.338% |
| Prime Medicine, Inc. | 193.85 Million USD | -14.782% |
| Aditxt, Inc. | 44.57 Million USD | -399.135% |
| Adagene Inc. | 115.72 Million USD | -92.265% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -4895.432% |
| Quantum-Si incorporated | 298.25 Million USD | 25.396% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | 85.041% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -2786.269% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | 36.659% |
| SciSparc Ltd. | 11.18 Million USD | -1889.859% |
| Vericel Corporation | 353.65 Million USD | 37.084% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -1721.937% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | -291.043% |
| Generation Bio Co. | 374.75 Million USD | 40.627% |
| Astria Therapeutics, Inc. | 254.66 Million USD | 12.628% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | -40.323% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | 34.819% |
| Invivyd, Inc. | 229.18 Million USD | 2.913% |
| Relay Therapeutics, Inc. | 843.98 Million USD | 73.636% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | -1728.421% |
| Spero Therapeutics, Inc. | 182.39 Million USD | -21.995% |
| Artelo Biosciences, Inc. | 20.42 Million USD | -989.434% |
| 2seventy bio, Inc. | 565.42 Million USD | 60.648% |
| ADMA Biologics, Inc. | 329.18 Million USD | 32.406% |
| Clene Inc. | 52.34 Million USD | -325.108% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | -278.835% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | -71.298% |
| GeoVax Labs, Inc. | 9.28 Million USD | -2296.863% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | 65.962% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | -114.751% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | -70.652% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | -128.09% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | -213.402% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | 8.265% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | 88.648% |
| Evaxion Biotech A/S | 12.88 Million USD | -1626.376% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | 11.725% |
| Verve Therapeutics, Inc. | 752.68 Million USD | 70.438% |
| Trevena, Inc. | 40.6 Million USD | -447.977% |
| Surrozen, Inc. | 46.08 Million USD | -382.869% |
| Tyra Biosciences, Inc. | 225.85 Million USD | 1.484% |
| Cingulate Inc. | 3.49 Million USD | -6272.908% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | -1238.06% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -238.721% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -1804.263% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | 17.135% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | 70.291% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | -76.744% |
| Clearmind Medicine Inc. | 4.32 Million USD | -5045.374% |
| Kronos Bio, Inc. | 213.27 Million USD | -4.326% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | -39.254% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -2499.184% |
| Viking Therapeutics, Inc. | 368.49 Million USD | 39.617% |
| Statera Biopharma, Inc. | 21.16 Million USD | -951.06% |
| ImmunityBio, Inc. | 504.45 Million USD | 55.892% |
| Korro Bio, Inc. | 221.66 Million USD | -0.38% |
| Kineta, Inc. | 10.28 Million USD | -2064.245% |
| BioVie Inc. | 25.2 Million USD | -782.668% |
| Codexis, Inc. | 136.56 Million USD | -62.935% |
| Celularity Inc. | 143.88 Million USD | -54.637% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | 64.979% |
| Celcuity Inc. | 191.21 Million USD | -16.362% |
| Virax Biolabs Group Limited | 5.48 Million USD | -3957.39% |
| Cibus, Inc. | 544.41 Million USD | 59.129% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | -76.741% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -983.07% |
| IN8bio, Inc. | 33.7 Million USD | -560.079% |
| Kodiak Sciences Inc. | 479.37 Million USD | 53.584% |
| Annexon, Inc. | 297.67 Million USD | 25.252% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | -28.609% |
| Assembly Biosciences, Inc. | 137.46 Million USD | -61.859% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | -959.906% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 92.559% |
| Eyenovia, Inc. | 28.77 Million USD | -673.144% |
| Puma Biotechnology, Inc. | 230.52 Million USD | 3.48% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -2980.094% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | -265.207% |
| Arcellx, Inc. | 825.13 Million USD | 73.034% |
| Cardiff Oncology, Inc. | 81.63 Million USD | -172.555% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | 51.867% |
| Regulus Therapeutics Inc. | 30.75 Million USD | -623.597% |
| Moolec Science SA | 24.05 Million USD | -825.131% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | 28.253% |
| Geron Corporation | 394.07 Million USD | 43.537% |
| LAVA Therapeutics N.V. | 101.71 Million USD | -118.765% |
| Royalty Pharma plc | 16.38 Billion USD | 98.642% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | 62.602% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -3081.013% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | -1750.005% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | 1.572% |
| Humacyte, Inc. | 128.22 Million USD | -73.53% |
| Structure Therapeutics Inc. | 482.01 Million USD | 53.839% |
| 89bio, Inc. | 596.26 Million USD | 62.684% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | 11.757% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -11927.351% |
| Genelux Corporation | 27.89 Million USD | -697.713% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | -148.88% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | 3.017% |
| Notable Labs, Ltd. | 19.54 Million USD | -1038.662% |
| Liquidia Corporation | 120.43 Million USD | -84.758% |
| Mustang Bio, Inc. | 17.74 Million USD | -1154.12% |
| Immunovant, Inc. | 666.71 Million USD | 66.626% |
| Quantum-Si incorporated | 298.25 Million USD | 25.396% |
| Arbutus Biopharma Corporation | 144.4 Million USD | -54.089% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | -310.831% |
| Vera Therapeutics, Inc. | 175.54 Million USD | -26.751% |
| Acasti Pharma Inc. | 73.3 Million USD | -203.555% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -4787.791% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -751.963% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | 76.938% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -4187.274% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | -876.717% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | -331.188% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | -23.142% |
| PepGen Inc. | 143.05 Million USD | -55.542% |
| Moleculin Biotech, Inc. | 38.21 Million USD | -482.217% |
| United Therapeutics Corporation | 7.16 Billion USD | 96.895% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | -1059.792% |
| Solid Biosciences Inc. | 164.93 Million USD | -34.902% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -3689.103% |
| Immuneering Corporation | 102.58 Million USD | -116.9% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -5064.206% |
| Silo Pharma, Inc. | 7.74 Million USD | -2772.475% |
| Belite Bio, Inc | 94.64 Million USD | -135.103% |
| XOMA Corporation | 234.3 Million USD | 5.034% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | 4.581% |
| Bionomics Limited | 27.64 Million USD | -704.75% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | 44.568% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -107.198% |
| uniQure N.V. | 831.68 Million USD | 73.246% |
| Cassava Sciences, Inc. | 151.66 Million USD | -46.711% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -4895.432% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | 18.759% |
| Forte Biosciences, Inc. | 38.98 Million USD | -470.821% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -5362.798% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | -504.127% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -2980.094% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -6233.789% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | -1782.294% |
| Altimmune, Inc. | 210.64 Million USD | -5.633% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 71.396% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -107.198% |
| Compugen Ltd. | 121.33 Million USD | -83.383% |
| Peak Bio, Inc. | 2.59 Million USD | -8469.739% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | -29.118% |
| Benitec Biopharma Inc. | 52.21 Million USD | -326.175% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | 34.913% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | -539.882% |
| Zura Bio Limited | 100.84 Million USD | -120.646% |
| PolyPid Ltd. | 15.37 Million USD | -1347.476% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | -86.532% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | -539.882% |
| Instil Bio, Inc. | 325.63 Million USD | 31.669% |
| argenx SE | 4.54 Billion USD | 95.102% |
| Immunome, Inc. | 148.54 Million USD | -49.795% |
| Compass Therapeutics, Inc. | 156.87 Million USD | -41.836% |
| Verona Pharma plc | 308.12 Million USD | 27.787% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | -155.875% |
| Shattuck Labs, Inc. | 159.56 Million USD | -39.446% |
| CervoMed Inc. | 9.97 Million USD | -2131.191% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | -18.068% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -1853.864% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | -24.024% |
| Moolec Science SA | 24.05 Million USD | -825.131% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -3537.217% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | -28.658% |
| AnaptysBio, Inc. | 452.38 Million USD | 50.815% |
| Design Therapeutics, Inc. | 289.64 Million USD | 23.179% |
| Leap Therapeutics, Inc. | 72.82 Million USD | -205.535% |
| NeurAxis, Inc. | 509.49 Thousand USD | -43571.614% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -4006.792% |
| Lumos Pharma, Inc. | 40.63 Million USD | -447.532% |
| Achilles Therapeutics plc | 161.45 Million USD | -37.812% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | -155.875% |
| 180 Life Sciences Corp. | 5.25 Million USD | -4130.574% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | -215.935% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -2499.184% |
| Nutriband Inc. | 7.51 Million USD | -2859.977% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | 12.635% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | -11.643% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | -191.957% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | -284.187% |
| MoonLake Immunotherapeutics | 526.54 Million USD | 57.742% |
| Palisade Bio, Inc. | 14.05 Million USD | -1483.447% |
| Tourmaline Bio, Inc. | 210.29 Million USD | -5.807% |
| Beam Therapeutics Inc. | 1.45 Billion USD | 84.757% |
| Neurogene Inc. | 222.57 Million USD | 0.03% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | 65.589% |
| AEON Biopharma, Inc. | 6.84 Million USD | -3150.636% |
| Sesen Bio, Inc. | 189.17 Million USD | -17.62% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | 18.156% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | -1522.725% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 71.486% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | 16.663% |
| Athira Pharma, Inc. | 160.24 Million USD | -38.854% |
| Vaccinex, Inc. | 3.63 Million USD | -6027.954% |
| HCW Biologics Inc. | 28.51 Million USD | -680.349% |
| XOMA Corporation | 234.3 Million USD | 5.034% |
| Nektar Therapeutics | 398.03 Million USD | 44.099% |
| Arvinas, Inc. | 1.3 Billion USD | 82.945% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -1205.991% |
| Merus N.V. | 458.49 Million USD | 51.47% |
| Omega Therapeutics, Inc. | 204.36 Million USD | -8.876% |
| Quince Therapeutics, Inc. | 180.2 Million USD | -23.475% |
| Rezolute, Inc. | 132.73 Million USD | -67.629% |
| Clene Inc. | 52.34 Million USD | -325.108% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | -1390.94% |
| BeyondSpring Inc. | 24.8 Million USD | -796.912% |
| Synlogic, Inc. | 75.55 Million USD | -194.515% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | -1775.788% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -2276.185% |
| Peak Bio, Inc. | 2.59 Million USD | -8469.739% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | -27.268% |
| Krystal Biotech, Inc. | 818.35 Million USD | 72.811% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | 7.458% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | 69.343% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -6120.162% |
| MannKind Corporation | 475.19 Million USD | 53.176% |
| Ikena Oncology, Inc. | 192.09 Million USD | -15.833% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | -1563.721% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | -90.928% |
| Gossamer Bio, Inc. | 311.91 Million USD | 28.665% |
| CohBar, Inc. | 16.36 Million USD | -1259.59% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | -532.784% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -2941.777% |
| Legend Biotech Corporation | 1.84 Billion USD | 87.964% |
| Mural Oncology plc | 301.74 Million USD | 26.26% |
| Biora Therapeutics, Inc. | 31.21 Million USD | -612.818% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -3817.08% |
| Disc Medicine, Inc. | 367.99 Million USD | 39.536% |
| Champions Oncology, Inc. | 26.13 Million USD | -751.469% |
| REGENXBIO Inc. | 573.97 Million USD | 61.234% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -8116.36% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -44.123% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | -1742.611% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | 34.564% |
| Vaxart, Inc. | 91.83 Million USD | -142.302% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | -271.438% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | -50.011% |
| Cellectis S.A. | 334.27 Million USD | 33.435% |
| Longeveron Inc. | 12.17 Million USD | -1727.114% |
| Repare Therapeutics Inc. | 253.9 Million USD | 12.365% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 93.184% |
| Inozyme Pharma, Inc. | 200.84 Million USD | -10.784% |
| Revolution Medicines, Inc. | 2.08 Billion USD | 89.347% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -13592.677% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | 19.879% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | -36.425% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | -60.372% |
| Anixa Biosciences, Inc. | 25.52 Million USD | -771.82% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 99.021% |
| Denali Therapeutics Inc. | 1.15 Billion USD | 80.717% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -1721.937% |
| Veru Inc. | 50.59 Million USD | -339.771% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | -388.455% |
| Cingulate Inc. | 3.49 Million USD | -6272.908% |
| Passage Bio, Inc. | 150.54 Million USD | -47.8% |
| Context Therapeutics Inc. | 16.06 Million USD | -1285.231% |
| Exicure, Inc. | 11.58 Million USD | -1821.468% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | 40.83% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | -37.654% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | -1173.5% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | 33.13% |
| Nuvalent, Inc. | 732.38 Million USD | 69.619% |
| ABVC BioPharma, Inc. | 14.94 Million USD | -1388.924% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | -148.46% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | -1467.937% |
| OmniAb, Inc. | 401.98 Million USD | 44.648% |
| Anew Medical, Inc. | 19.45 Million USD | -1043.64% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | -732.528% |
| Lipocine Inc. | 23 Million USD | -867.372% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | -59.152% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | 27.182% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -165.073% |
| G1 Therapeutics, Inc. | 121.54 Million USD | -83.072% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -2704.108% |
| Sage Therapeutics, Inc. | 882.27 Million USD | 74.78% |
| Ocugen, Inc. | 64.54 Million USD | -244.719% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | -78.661% |
| Q32 Bio Inc. | 306.11 Million USD | 27.314% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -5187.69% |
| Alumis Inc. Common Stock | 89.61 Million USD | -148.299% |
| Equillium, Inc. | 50.53 Million USD | -340.344% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | -195.905% |
| Coya Therapeutics, Inc. | 41.27 Million USD | -439.101% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -12982.024% |
| Galera Therapeutics, Inc. | 26.14 Million USD | -751.176% |
| Evelo Biosciences, Inc. | 64.44 Million USD | -245.286% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -5869.929% |
| Dominari Holdings Inc. | 57.55 Million USD | -286.577% |
| Edesa Biotech, Inc. | 8.89 Million USD | -2402.757% |
| vTv Therapeutics Inc. | 11.01 Million USD | -1919.477% |
| Bio-Techne Corporation | 2.81 Billion USD | 92.091% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 76.256% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | 72.579% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | 19.865% |
| Candel Therapeutics, Inc. | 41.7 Million USD | -433.562% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | 66.67% |
| Nkarta, Inc. | 378.88 Million USD | 41.273% |
| BioCardia, Inc. | 2.98 Million USD | -7349.146% |
| Iterum Therapeutics plc | 26.25 Million USD | -747.351% |